Fulgent Genetics (Fulgent Genetics) Risk Assessment

View and export this data going back to 2016. Start your Free Trial

What is Fulgent Genetics Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Fulgent Genetics is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Fulgent Genetics's Risk Assessment

For the Diagnostics & Research subindustry, Fulgent Genetics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fulgent Genetics's Risk Assessment Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Fulgent Genetics's Risk Assessment falls into.

Fulgent Genetics (NAS:FLGT) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Fulgent Genetics Risk Assessment Related Terms

Thank you for viewing the detailed overview of Fulgent Genetics's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Fulgent Genetics (Fulgent Genetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (NAS:FLGT) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

7F0:Germany 7F0:Germany

Address

4978 Santa Anita Avenue, Temple City, CA, USA, 91780

Website

https://www.fulgentgenetics.com

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Executives

Jian Xie	officer: Chief Operating Officer	C/O FULGENT GENETICS, INC., 4399 SANTA ANITA AVE, EL MONTE CA 91731
Hanlin Gao	10 percent owner, officer: Chief Scientific Officer	4399 SANTA ANITA AVE., EL MONTE CA 91731
Paul Kim	officer: CFO and Treasurer	4399 SANTA ANITA AVE, EL MONTE CA 91731
Regina E Groves	director	5751 COPLEY DRIVE, SAN DIEGO CA 92111
Leonard E Post	director
Michael Nohaile	director	C/O BIO AI ACCELERATION COMPANY, 20 UNIVERSITY AVENUE, CAMBRIDGE MA 02138
John C Bolger	director	4978 SANTA ANITA AVENUE, SUITE 205, TEMPLE CITY CA 91780
Ming Hsieh Trust	10 percent owner	4399 SANTA ANITA AVE., EL MONTE CA 91731
Linda Marsh	director	100 N. STONEMAN AVE., ROOM 200, ALHAMBRA CA 91801
Ming Hsieh	director, 10 percent owner, officer: President and CEO	4399 SANTA ANITA AVE., EL MONTE CA 91731
Fulgent Genetics, Inc.	director	4399 SANTA ANITA AVE, EL MONTE CA 91731
Yun Yen	director	1301 OAKLAWN ROAD, ARCADIA CA 91006
James Mulay	director	6521 THOROUGHBRED LOOP, ODESSA FL 33556
Xi Long Usa, Inc.	10 percent owner	#6 XINRUI RD., SCIENCE CITY, LUOGANG DISTRICT, GUANGZHOU CITY F4 510663